What does this research mean for the field?

Routine reductions in radioactive iodine activity for hemodialyzed patients with thyroid cancer are unnecessary, as standard doses remain below bone marrow toxicity thresholds and yield favorable oncologic outcomes. Novelty: ClaimNovelty.CONTRADICTORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The study aims to improve management strategies for hemodialyzed patients treated with radioactive iodine for thyroid cancer.

May 16, 2026Journal of Nuclear Medicine

Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience

View Full Paper

Ask AI

Bookmark

Authors

BCB CHEVALIERCentre National de la Recherche Scientifique LDLaura DevosInserm CBC. BailletPancreatic Cancer Action Network

Discussion

Member takes

Implication

Randomized trial evaluates radioactive iodine management in hemodialyzed patients, suggesting improved outcomes.

Key Points

The study aims to improve management strategies for hemodialyzed patients treated with radioactive iodine for thyroid cancer.
Included all hemodialyzed patients requiring radioactive iodine for thyroid cancer at a tertiary referral center.
Evaluated oncologic results and toxicity risk while estimating blood marrow absorbed doses based on different models.
Reviewed dialysis parameters and the impact of two recombinant human thyrotropin administration schemas.
Total of 16 patients included; 15 managed with recombinant human thyrotropin.
Median radioactive iodine activity was 2913 MBq, with good tolerance observed.
Median blood marrow absorbed doses were statistically different among three models, with no patient exceeding the 2-Gy threshold.

Cite This Study

CHEVALIER et al. (2026) studied this question.

synapsesocial.com/papers/6a080a29a487c87a6a40c151 https://doi.org/10.2967/jnumed.125.271707

View Full Paper

Ask AI

Bookmark

May 16, 2026Journal of Nuclear Medicine

Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience

View Full Paper

Ask AI

Bookmark

Authors

BCB CHEVALIERCentre National de la Recherche Scientifique LDLaura DevosInserm CBC. BailletPancreatic Cancer Action Network

Discussion

Member takes

Implication

Randomized trial evaluates radioactive iodine management in hemodialyzed patients, suggesting improved outcomes.

Key Points

The study aims to improve management strategies for hemodialyzed patients treated with radioactive iodine for thyroid cancer.
Included all hemodialyzed patients requiring radioactive iodine for thyroid cancer at a tertiary referral center.
Evaluated oncologic results and toxicity risk while estimating blood marrow absorbed doses based on different models.
Reviewed dialysis parameters and the impact of two recombinant human thyrotropin administration schemas.
Total of 16 patients included; 15 managed with recombinant human thyrotropin.
Median radioactive iodine activity was 2913 MBq, with good tolerance observed.
Median blood marrow absorbed doses were statistically different among three models, with no patient exceeding the 2-Gy threshold.

Cite This Study

CHEVALIER et al. (2026) studied this question.

synapsesocial.com/papers/6a080a29a487c87a6a40c151 https://doi.org/10.2967/jnumed.125.271707

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark